ArticleWorld journal of urology2016
Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma.
Article in World journal of urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 60 citations in OpenAlex.
- Immune checkpoint TIM-3 in tumor immunotherapy.Acta biochimica et biophysica Sinica · 2026Review
- Quantitative analysis of lymphocyte exhaustion markers in patients with localized clear cell renal cell carcinoma.Oncology letters · 2025Article
- First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors.The oncologist · 2025Article
- The role of immune checkpoints PD-1 and CTLA-4 in cardiovascular complications leading to heart failure.Frontiers in immunology · 2025Review
- Simultaneous targeting of Tim3 and A2a receptors modulates MSLN-CAR T cell antitumor function in a human cervical tumor xenograft model.Frontiers in immunology · 2024Article
- Immune checkpoint inhibitors associated cardiovascular immune-related adverse events.Frontiers in immunology · 2024Review
- Review
- TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors.Cancer immunology, immunotherapy : CII · 2023Review
- Biomarkers for Immune Checkpoint Inhibitors in Renal Cell Carcinoma.Journal of clinical medicine · 2023Review
- Combined Immune Checkpoint Blockade Enhances Antiviral Immunity against Bovine Leukemia Virus.Journal of virology · 2023Article
- Technology meets TILs: Deciphering T cell function in the -omics era.Cancer cell · 2023Review
- Emerging resistanceCancer drug resistance (Alhambra, Calif.) · 2023Review
- Spatial distribution and functional analysis define the action pathway of Tim-3/Tim-3 ligands in tumor development.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy.Computational and structural biotechnology journal · 2022Review
- The roles of exosomal immune checkpoint proteins in tumors.Military Medical Research · 2021Review
- Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics.International journal of molecular sciences · 2021Review
- Can Immune Suppression and Epigenome Regulation in Placenta Offer Novel Insights into Cancer Immune Evasion and Immunotherapy Resistance?Epigenomes · 2021Review
- Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.Nature reviews. Clinical oncology · 2021Review
- Tumor-infiltrating CD8Drug discovery today · 2021Review
- Low Distribution of TIM-3Journal of immunology research · 2021Article
Corrections and comments
- Expression of concern · 2023-01-23Author Unresponsive · False/Forged Affiliation ·
- Erratum issued
- Expression of concern
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRenal cell carcinoma (RCC) is the most common cancer of kidney. Evidences have shown that RCC is sensitive to various immunotherapies. Tim-3 plays a role in suppressing Th1-mediated immune responses. However, no study has yet examined the effect of Tim-3 on tumor infiltrating lymphocytes (TILs) in RCC.
methodsWe investigated the expression and function of Tim-3 on TIL CD4+ T cells and TIL CD8+ T cells from 30 RCC patients.
resultsLevels of Tim-3 were significantly increased on both TIL CD4+ T cells and TIL CD8+ T cells and were associated with higher stages of the cancer. Also, GATA-3 and interferon gamma (IFN-γ) were down-regulated, whereas T-bet was up-regulated in TIL Tim-3+ T cells, indicating that Tim-3 expression defined a population of dysfunctional TIL Th1/Tc1 cells. Mechanism analyses showed that TIL Tim-3-expressing CD8+ T cells exhibited impaired Stat5 and p38 signaling pathway. Blocking the Tim-3 pathway restored cell proliferation and increased IFN-γ production in TIL CD4+ and CD8+ T cells of RCC.
conclusionsThese results suggest that Tim-3 may be used as a novel target for increasing immune responses in RCC tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.